Hyperfine, Inc. Class A (HYPR)

Over the past six months, Hyperfine completed an equity offering, held its Q3 2025 earnings call, and announced global expansion through distribution agreements. Clinical data publication demonstrated the Swoop® system's enhanced stroke detection capabilities, leading to a stock increase. Hyperfine reported strong Q4 2025 revenue and provided 2026 revenue guidance. Horizon Technology Finance provided a loan facility, and analyst ratings were adjusted by Zacks Research and Lake Street Capital.

Hyperfine, Inc. has shown some demand seasonality based on six years of historical data. July has been the strongest month, while October tends to be the weakest month. However, the consistency score for this seasonal pattern is rated as "Poor", indicating low reliability across different market conditions.

Hyperfine, Inc. is a health technology company specializing in medical devices, operating within the Healthcare sector, specifically in the Medical Devices and electromedical and electrotherapeutic apparatus manufacturing industries. Its primary product is the Swoop® Portable MR Imaging® System, the first FDA-cleared portable, ultra-low-field magnetic resonance brain imaging system designed for brain imaging at various points of care. Hyperfine's business model includes device sales, service, and software revenue, encompassing subscriptions, maintenance, and AI-powered imaging software like Optive AI™.

Hyperfine, Inc. has a growing global presence with the Swoop® system FDA cleared in the United States and holding CE Mark in the European Union and UKCA Mark in the United Kingdom, as well as regulatory approval in India. The company's products are commercially available in North America, Europe, Asia, Oceania, and the Middle East. Recent expansion efforts in 2024 and 2025 have focused on establishing distribution agreements in additional European markets, Turkey, Israel, Saudi Arabia, Malaysia, and Indonesia.

Hyperfine's brand reputation has been positively influenced by its innovative technology, FDA clearance for the Swoop® system, and publications demonstrating enhanced stroke detection and health economic benefits. Positive clinical study results and the company's mission to make MRI more accessible contribute to a positive brand image. Despite financial challenges, the company's product and brand perception in the medical community remains positive.

Hyperfine, Inc. has a mix of institutional, insider, and retail owners. As of March 2026, 15.86% of Hyperfine's stock is owned by institutional investors, 27.52% by Hyperfine insiders, and 56.61% by retail investors. Major institutional owners include Vanguard Group Inc, Sio Capital Management, LLC, and Fosun International Ltd. Jonathan M. Rothberg, the founder of Hyperfine, is the largest individual shareholder.